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Abstract
Background: Previous studies found regional differences in the prevalence and incidence of type 2 diabetes between
Northeast and South of Germany. The aim of this study was to investigate if regional variations are also present
for macrovascular disease in people with type 2 diabetes and in the general population. A further aim was to
investigate if traditional risk factors of macrovascular complications can explain these regional variations.
Methods: Data of persons aged 30–79 from two regional population-based studies, SHIP-TREND (Northeast Germany,
2008–2012, n = 2539) and KORA-F4 (South Germany, 2006–2008, n= 2932), were analysed. Macrovascular disease was
defined by self-reported previous myocardial infarction, stroke or coronary angiography. Multivariable logistic regression
was performed to estimate odds ratios (OR) and 95% confidence intervals (CI) for prevalence of macrovascular disease in
persons with type 2 diabetes and in the general population.
Results: The prevalence of macrovascular disease in persons with type 2 diabetes and in the general population was
considerably higher in the Northeast (SHIP-TREND: 32.8 and 12.0%) than in the South of Germany (KORA-F4: 24.9 and 8.
8%), respectively. The odds of macrovascular disease in persons with type 2 diabetes was 1.66 (95% CI: 1.11–2.49) in the
Northeast in comparison to the South after adjustment for sex, age, body mass index, hypertension, hyperlipidemia and
smoking. In the general population, SHIP-TREND participants also had a significantly increased odds of macrovascular
disease compared to KORA-F4 participants (OR = 1.63, 95% CI: 1.33–2.00). After excluding coronary angiography
(myocardial infarction or stroke only), the ORs for region decreased in all models, but the difference between SHIP-TREND
and KORA-F4 participants was still significant in the age- and sex-adjusted model for the general population (OR = 1.34,
95% CI: 1.01–1.78).
Conclusions: This study provides an indication for regional differences in macrovascular disease, which is not explained
by traditional risk factors. Further examinations of other risk factors, such as regional deprivation or geographical variations
in medical care services are needed.
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Background
The prevalence of type 2 diabetes rises steadily all over
the world [1, 2]. In 2014, there were considerable
regional differences in the prevalence of type 2 diabetes
in Europe ranging from 2.4% in Moldova to 14.9% in
Turkey [3]. Interestingly, the prevalence of type 2
diabetes shows regional variations even within Germany
[4]. In a meta-analysis of regional population-based sur-
veys, a substantially higher prevalence of 12.0% in the
East (CARLA) and 10.9% in the Northeast (SHIP) was
reported, compared to 5.8% in the South (KORA-S4) of
Germany [4]. Incidence of type 2 diabetes exhibits simi-
lar differences being highest in the East and lowest in
the South of Germany [5]. Nevertheless, it remains
unclear, whether more frequently performed screening
tests or a higher morbidity led to a higher diabetes
prevalence and incidence in the Northeast than in other
regions. However, according to pooled population-based
data from the same regions of Germany, there is also a
considerably higher prevalence of prediabetes and
undiagnosed type 2 diabetes in the Northeast than in the
South [6].
Patients with type 2 diabetes are at increased risk for
diabetes-related macrovascular complications, such as
coronary heart disease, stroke or peripheral vascular
disease [7, 8]. These complications lead to a reduced
quality of life and premature death [9, 10]. Altogether,
diabetes-related complications represent a growing
social and economic health problem [11]. Knowledge
about regional differences in macrovascular disease and
related risk factors are necessary to identify high risk
groups and to plan specific strategies for its prevention.
The aim of this analysis was to investigate, if regional
variations are also existent for the prevalence of macro-
vascular disease in people with type 2 diabetes and in
the general population. A further aim was to investigate
if traditional risk factors of macrovascular complications
can explain these regional differences.
Methods
Study populations
The SHIP-TREND study (Northeast of Germany)
The SHIP-TREND study region is located in the
Northeast of Germany, the part of the former German
Democratic Republic (GDR). A stratified random sample
of 8826 adults aged 20–79 years with German nationality
was drawn from a central population registry of Western
Pomerania (212,157 inhabitants) with the aim to assess
prevalence and incidence of common risk factors,
subclinical disorders and clinical diseases in the German
population. A two-stage cluster sampling method was
used which followed the WHO Multinational Monitor-
ing of Trends and Determinants in Cardiovascular
Disease (MONICA) Project in Germany. Stratification
variables were age, sex, and city/county of residence. Of
all persons invited, 4420 (50.1%) individuals participated
in the examinations between 2008 and 2012. All partici-
pants provided written informed consent and the
medical ethics committee of the University of Greifswald
approved the study protocol. Further information on the
study design of the SHIP-TREND study has been
previously published [12].
The KORA-F4 study (South of Germany)
The KORA-F4 study (2006–2008) is the 7-year follow-up
of the KORA-S4 study (1999–2001), a population-based
health survey which was carried out in the city of Augsburg
and 16 municipalities from the surrounding counties (about
600,000 inhabitants), which is part of the former Federal
Republic of Germany (FRG). The survey sampling method
of the former WHO MONICA project was used. Within
each selected community, a stratified sample with ten equal
strata by sex and age was drawn. As in SHIP-TREND, only
individuals with German citizenship and main residency in
the study area were included. Of the 4261 participants aged
25–74 years in S4, 3080 took part in the F4 study (72.3%).
The loss of participants from S4 to F4 occurred due to
deaths (n = 176), demands for the deletion of data (n = 12),
or because participants were completely lost to the
follow-up (206), could not be contacted (n = 174), were
unable to come (n = 218) or refused to participate (n = 395)
[13]. All study participants gave written informed consent
to the study. The study design was approved by the ethics
committee of the Bavarian Medical Association. The study
design, sampling method and data collection have been
described in detail elsewhere [14].
Variables
In both studies, information on sociodemographic
variables, lifestyle habits and medical history were
collected by trained and certified staff during standard-
ized personal interviews [12, 14].
Macrovascular disease
Macrovascular disease was defined as having a
self-reported previous myocardial infarction, stroke or a
coronary angiography and was not validated by a physi-
cian’s assessment.
The variable “coronary angiography” did not include
participants who also had a previous myocardial infarc-
tion. As myocardial infarction is one of the most com-
mon indication for a coronary angiography [15], the
participants who had a myocardial infarction were most
probably already included in the corresponding variable.
Diabetes and glucose tolerance
Known type 2 diabetes was defined using self-reported
physician’s diagnosis of diabetes. In KORA-F4, this
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information was validated by a physician [6]. The 75-g
oral glucose tolerance tests (OGTT) were carried out in
all participants without known diabetes according to
concordant standardised operating procedures in both
studies [14]. However, measurements of fasting glucose
and 2-h glucose were based on plasma in SHIP-TREND
and on serum in KORA-F4. To examine whether the
values are comparable, duplicate measurements were
performed using serum samples of all SHIP-TREND
participants. The analysis revealed, that both measure-
ments were highly correlated (r = 0.99, p < 0.0001) and
showed a very good concordance [6]. Moreover, 30
serum blood glucose samples were randomly taken from
KORA-F4 and reassessed in the SHIP-TREND labora-
tory; the calculated correlation coefficient was 0.94 (p <
0.0001). On average, these original 30 KORA-F4 mea-
surements were only slightly lower (mean − 0.06 mmol/l;
SD = 0.17) [6]. Hence, it was decided to regard the
serum glucose values from KORA-F4 and plasma glu-
cose values from SHIP-TREND as comparable for the
current study.
Depending on the OGTT results, participants were
categorised to three distinctive groups [16]: Normal glu-
cose tolerance (fasting glucose values < 5.6 mmol/l (<
100 mg/dl) and 2-h glucose < 7.8 mmol/l (< 140 mg/dl)),
prediabetes (fasting glucose 5.6–6.9 mmol/l (100–125
mg/dl) and/or 2-h glucose values 7.8–11.0 mmol/l (140–
199 mg/dl)) and newly diagnosed diabetes (fasting glu-
cose values ≥7.0 mmol/l (≥ 126 mg/dl) or 2-h glucose
≥11.1 mmol/l (≥ 200 mg/dl)).
Medical data
Anthropometric measurements were taken after remov-
ing shoes, heavy clothing and belts. Body mass index
(BMI) was calculated as weight [kg] divided by height2
[m2]. Blood pressure measurements were taken at the
right arm after a rest period of at least five minutes in a
sitting position and repeated three times at an interval
of three minutes. The mean of the second and third
measurement was calculated. A fasting venous blood
sample was obtained from all study participants while
sitting. Triglycerides were measured with the
GPO-PAP-method (TGL Flex, Dade Behring, Marburg,
Germany). Plasma high-sensitivity C-reactive protein
(hsCRP) concentrations were measured using a latex
enhanced nephelometric assay run on a BN II analyser
(Dade Behring, Marburg, Germany). HsCRP values
higher than 10mg/l were excluded from the analysis to
include only participants with subclinical inflammation.
Glycated hemoglobin (HbA1c) was measured by
high-performance liquid chromatography with spectro-
photometric detection (Diamat Analyzer; Bio-Rad,
Munich, Germany) and a coefficient of variation of 1.5%.
The insulin resistance score (HOMA-IR) was calculated
as fasting plasma glucose (mmol/l) × fasting serum
insulin (mlU/l) / 22.5.
Hypertension and hyperlipidemia
During the interview, the participants were asked
whether a doctor had ever diagnosed increased/high
blood pressure or increased blood lipids in the last 12
months. Furthermore, they were asked to bring original
packaging of their medications used during the last 7
days. Finally, the variables “hypertension” and “hyperlip-
idemia” were defined as follows: hypertension as
self-reported increased/high blood pressure or intake of
antihypertensive drugs, hyperlipidemia as self-reported
increased blood lipids or intake of lipid-lowering drugs.
Educational level
In both studies, the participants were asked for their
highest school degree achieved. Educational level was
defined as low and middle (less than university qualifica-
tion) or high level (university qualification). According
to the German school system, low educational level
includes participants with up to 9 years of schooling.
Middle educational level is equivalent to 10 years of
schooling and high educational level to 12 or 13 years of
schooling, which is the general qualification for
university entrance [17].
Physical activity
Physical activity during leisure time was assessed by
self-report. Participants were classified as active if they
reported regular participation in sports in summer and
winter and being active for > 1 h per week in both
seasons [18].
Smoking
Three categories (current, ex- and non-smoker) were
defined. Participants were classified as current smokers
if they smoked at least one cigarette per day regularly, or
if they had stopped smoking less than 12months ago.
Persons were defined as ex-smokers if they had stopped
smoking more than 12months ago and as non-smokers
if they had either never smoked or less than one
cigarette per day [18, 19].
Study sample
The converged data set contained participants aged 30
to 79 years (SHIP-TREND: n = 3960, KORA-F4: n =
3022). Participants were excluded from the analysis if
they had type 1 diabetes (SHIP-TREND: n = 62,
KORA-F4: n = 9) and missing information on known
diabetes or missing or implausible values in glucose
measurements (SHIP-TREND: n = 615, KORA-F4: n =
81). All participants who underwent glucose tolerance
testing were instructed to fast for at least 8 h prior to the
Ptushkina et al. BMC Public Health         (2018) 18:1331 Page 3 of 13
test. In SHIP-TREND, however, 744 participants without
known diabetes did not fulfill this requirement. These
participants were also excluded from the analysis. There-
fore, the present study is based on 2539 SHIP-TREND
(Northeast) and 2932 KORA-F4 (South) participants.
Statistical analyses
For descriptive statistics, means and standard devia-
tions (SD) were calculated for normally distributed
continuous variables, while variables with skewed
distribution were described as medians and interquar-
tile ranges. For categorical variables percentages are
reported. Because triglycerides, hsCRP and HOMA-IR
were not normally distributed, these variables were
transformed using the log function to correct the
skewness. Differences between groups were assessed
using T-test for continuous variables and Chi-square
test or univariate logistic regression model for
categorical variables. The p-values for study differ-
ences in components of metabolic syndrome were
corrected using the step-down Bonferroni procedure
to account for multiple comparisons (level of signifi-
cance p < 0.05). Logistic regression models were used
to identify factors related to macrovascular disease.
Three different models were fitted: model A adjusted
for sex and age, model B adjusted for sex, age, BMI,
hsCRP, hypertension, hyperlipidemia, smoking, educa-
tion and physical activity, and model C adjusted for
significant variables in models B and the OGTT
groups. All models were separately fitted for partici-
pants with known type 2 diabetes and for the general
population, respectively. Sensitivity analyses (using
BMI as a continuous instead of a categorical variable
and definition of “macrovascular disease” as having
myocardial infarction or stroke only) were performed
to test the robustness of conclusions. A two-sided
alpha level of 0.05 was chosen as criterion for statis-
tical significance. All analyses were carried out using
SAS, version 9.4 (SAS Institute Inc., Cary, NC, USA).
Results
Participants’ characteristics stratified by cohort and
diabetes status
The baseline characteristics of the participants strati-
fied by cohort are presented in Table 1. SHIP-TREND
participants (Northeast) were somewhat younger than
KORA-F4 participants (South) and were diagnosed
with having type 2 diabetes at an earlier age, whereas
the sex distribution was similar. Furthermore,
SHIP-TREND participants had a higher BMI, blood
pressure values, triglycerides and hsCRP, as well as
higher fasting and 2-h glucose values. Participants of
both regions slightly differed in mean HbA1c, total
and LDL-cholesterol, but not in HDL-cholesterol.
Moreover, SHIP-TREND participants reported current
smoking significantly more often than KORA-F4
participants. Low and middle educational levels were
more frequently found in KORA-F4. The prevalence
of macrovascular disease among participants with
known diabetes and in the general population was
significantly higher in SHIP-TREND than in
KORA-F4.
Risk factors, which are associated with cardiovascular
disease (metabolic syndrome) [20], stratified by
OGTT-status (normal glucose tolerance, prediabetes,
newly diagnosed diabetes and known diabetes) are
reported in Table 2. The prevalence of prediabetes,
newly diagnosed diabetes and known diabetes was
higher in SHIP-TREND participants (Northeast) than in
KORA-F4 participants (South). The proportions of
participants with macrovascular disease were also higher
in the Northeast compared to the South in people with
normal glucose tolerance, newly diagnosed diabetes and
known diabetes, but not in persons with prediabetes.
The results of Table 2 confirmed the expectation that
the prevalence of risk factors associated with cardiovas-
cular disease increase with increasing blood glucose
levels.
Mean total cholesterol was similar in both studies in
the normal glucose tolerance group (5.5 mmol/l), in
people with prediabetes (5.7 mmol/l) and in the newly
diagnosed diabetes group (5.6 mmol/l), respectively. In
participants with known diabetes, it was slightly lower in
SHIP-TREND (5.1 mmol/l) than in KORA-F4 (5.3
mmol/l). LDL-cholesterol was also somewhat lower in
SHIP-TREND than in KORA-F4 in all OGTT groups.
Insufficient physical activity (less than 1 h/week) was
more common in participants in the Northeast (SHIP--
TREND), except in the group of known diabetes (54% in
SHIP-TREND vs. 62% in KORA-F4). The prevalence of
current smokers was higher in SHIP-TREND, but not in
the group of newly diagnosed diabetes (12% in
SHIP-TREND, 14% in KORA-F4). The percentages of
participants who smoked were highest in the group of
normal glucose tolerance (24% in SHIP-TREND, 20% in
KORA-F4) and lowest in the group of newly diagnosed
diabetes in SHIP-TREND (12%) and in the group of
known diabetes in KORA-F4 (11%). The prevalence of
people who had stopped smoking was highest in groups
of newly diagnosed diabetes (20% in SHIP-TREND, 36%
in KORA-F4) and known diabetes (32% in
SHIP-TREND, 35% in KORA-F4), and lowest in people
with normal glucose tolerance (17% in SHIP-TREND,
22% in KORA-F4). Low or middle educational status
tended to be more often in participants with known
diabetes (about 86% in both studies) and less frequently
in people with normal glucose tolerance (70% in
SHIP-TREND and 72% in KORA-F4).
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Table 1 Baseline participant characteristics by cohort and p-values for study differences
SHIP-TREND KORA-F4 p-value
N 2539 2932
Age (years) 53.9 (12.9) 55.7 (12.8) < 0.001
Female sex (%) 52.8 51.6 0.373
Middle/low education (%) 73.5 76.3 0.021
Age at diagnosis of diabetes (years)a 55.2 (10.5) 59.1 (10.1) < 0.001
Body mass index (kg/m2) 28.6 (5.3) 27.6 (4.8) < 0.001
No physical activity (%) 48.6 45.0 0.009
Current smoking (%) 19.6 16.6 0.064
Ex-smoking (%) 21.4 26.5 0.001
Systolic blood pressure (mmHg) 127.7 (18.2) 122.2 (18.6) < 0.001
Diastolic blood pressure (mmHg) 77.3 (10.0) 75.2 (10.0) < 0.001
Hypertension in general population (%) 52.9 50.8 0.125
Self-reported high blood pressure (ever) (%) 48.9 48.6 0.823
Antihypertensive medication (%) 38.4 29.8 < 0.001
Hypertension in known diabetes (%)a 88.9 88.2 0.782
Self-reported high blood pressure (ever) (%) 80.0 84.8 0.141
Antihypertensive medication (%) 79.2 75.1 0.237
Hyperlipidemia in general population (%) 27.6 30.5 0.020
Self-reported high lipid levels (last 12 months) (%) 24.5 28.2 0.002
Lipid-lowering medication (%) 14.2 12.3 0.042
Hyperlipidemia in known diabetes (%)a 59.6 59.5 0.988
Self-reported high lipid levels (last 12 months) (%) 46.0 48.6 0.539
Lipid-lowering medication (%) 41.8 39.2 0.529
Macrovascular disease in general population (%) 12.0 8.8 < 0.001
Myocardial infarction (%) 2.9 2.9 0.976
Stroke (%) 1.5 1.0 0.052
Coronary angiography (%)b 8.6 5.2 < 0.001
Macrovascular disease in known diabetes (%)a 32.8 24.9 0.040
Myocardial infarction (%) 9.4 11.0 0.544
Stroke (%) 4.7 2.5 0.172
Coronary angiography (%)b 22.2 12.3 0.002
Fasting glucose (mmol/l)c 5.5 (0.8) 5.3 (0.6) < 0.001
2-h glucose (mmol/l)c 6.6 (2.4) 6.2 (2.0) < 0.001
HbA1c (%) 5.46 (0.89) 5.55 (0.61) < 0.001
HbA1c (mmol/mol) 36.1 (9.7) 37.1 (6.7) < 0.001
HOMA-IRd 2.5 (1.6–3.8) 2.0 (1.4–3.0) < 0.001
Total cholesterol (mmol/l) 5.5 (1.1) 5.6 (1.0) 0.009
HDL-cholesterol (mmol/l) 1.4 (0.4) 1.4 (0.4) 0.167
LDL-cholesterol (mmol/l) 3.4 (0.9) 3.5 (0.9) < 0.001
Triglycerides (mmol/l) 1.3 (0.9–1.9) 1.2 (0.8–1.7) < 0.001
hsCRP (mg/l)e 1.2 (0.7–2.6) 1.1 (0.6–2.4) < 0.001
eGFR (ml/min/1.73 m2) 86.9 (20.1) 88.3 (16.5) 0.005
Results are means (± SD), percentages or medians (IQR)
aSHIP-TREND: N = 344, KORA-F4: N = 237
bParticipants with previous myocardial infarction were excluded
cParticipants without known diabetes, SHIP-TREND: N = 2178, KORA-F4: N = 2695
dParticipants without known diabetes, SHIP-TREND: N = 1953, KORA-F4: N = 2665
ehigh-sensitivity C - reactive protein. Participants with hsCRP > 10mg/l were excluded, SHIP-TREND: N = 175, KORA-F4: N = 112
Significant regional differences (p < 0.05) are highlighted in bold
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Regional differences and risk factors of macrovascular
disease
We performed logistic regression analyses with macro-
vascular disease as dependent variable separately in
persons with known diabetes and in the general popula-
tion (Table 3). In a model adjusted for sex and age
(model A), SHIP-TREND participants (Northeast) with
known diabetes had a higher odds (odds ratio (OR))
(OR = 1.66; 95% CI 1.14–2.43) of having macrovascular
disease compared to KORA-F4 participants (South).
When the model was further adjusted for BMI, hsCRP,
hypertension, hyperlipidemia, smoking, education and
physical activity (model B), the OR slightly increased to
1.70 (95% CI 1.11–2.62). In the final model, adjusted for
sex, age, BMI, hypertension, hyperlipidemia and smoking
(model C), SHIP-TREND participants still had signifi-
cantly increased odds of having macrovascular disease
compared to KORA-F4 participants (OR = 1.66, 95% CI
1.11–2.49). In this final model, age, hypertension and
hyperlipidemia were significantly positively related to
macrovascular disease.
Fitting logistic regression models, adjusting for age
and sex and including all study participants (model A),
we found that persons in the Northeast (SHIP-TREND)
also had a significantly higher odds for having myocar-
dial infarction, stroke or coronary angiography (OR =
1.76, 95% CI 1.46–2.12) compared to participants in the
South (KORA-F4). In model B, adjusted for further risk
factors, the OR for region increased to 1.78 (95% CI
1.44–2.19). In model C, adjusted for sex, age, BMI,
hypertension, hyperlipidemia, smoking and OGTT
groups (known diabetes, prediabetes, newly diagnosed
diabetes, normal glucose tolerance as reference), the
odds slightly decreased to 1.63 (95% CI 1.33–2.00). In
the general population, known diabetes was associated
with an increased odds of having macrovascular disease
(OR = 1.37, 95% CI 1.03–1.84) compared to participants
with normal glucose tolerance. Sex, age, BMI, hyperten-
sion, hyperlipidemia and smoking were also significantly
positively related to macrovascular complications.
Sensitivity analyses
First, a sensitivity analyses was carried out to evaluate
the effect of using BMI as a continuous instead of a cat-
egorical variable for obesity. The OR for macrovascular
disease in SHIP-TREND participants (Northeast) com-
pared to KORA-F4 participants (South) remained almost
unchanged in all models. In the second sensitivity ana-
lysis (Table 4), we excluded coronary angiography from
the definition of “macrovascular disease” (myocardial
infarction or stroke only). The ORs for region decreased
in all models, but the difference between SHIP-TREND
and KORA-F4 participants was still significant in the
age- and sex-adjusted model for the general population
(OR = 1.34, 95% CI 1.01–1.78). We did not find any
interaction of the variable “OGTT group” (normal
glucose tolerance, prediabetes, newly diagnosed diabetes
or known diabetes) and cohort (SHIP-TREND,
KORA-F4) in people with prediabetes, known diabetes
as well as for newly diagnosed diabetes.
Discussion
Our analyses suggested a higher prevalence of macrovas-
cular disease in the Northeast than in the South of
Germany in persons with known type 2 diabetes as well
as in the general population. SHIP-TREND participants
(Northeast) had significantly increased odds of having
myocardial infarction, stroke or a coronary angiography
compared to KORA-F4 participants (South). After
excluding coronary angiography from the outcome
definition, significant regional differences for cardiovas-
cular events were still present in the general population.
In people with type 2 diabetes, macrovascular disease
had a positively significant relationship with higher age,
hypertension and hyperlipidemia. In the general popula-
tion, male sex, higher age, overweight and smoking were
positively associated with macrovascular disease. How-
ever, these traditional risk factors were not able to fully
explain the regional differences.
The regional variation in macrovascular disease within
Germany is in line with previous studies on prevalence
and mortality of cardiovascular disorders in German
federal states [21–24]. The results from the nationwide
telephone health survey in Germany (German Health
Update (GEDA) from 2009-2012) on regional differences
in the prevalence of cardiovascular disease with 62,214
participants showed that the prevalence of myocardial
infarction, coronary heart disease, heart failure or stroke
varied between nearly 13% in the North and 10% in the
South [21]. Furthermore, the data from the Federal
Statistical Office of Germany demonstrated
age-standardized mortality rates from ischaemic heart
disease of 169–177 per 100,000 persons in the Northeast
and 95–105 per 100,000 persons in the South [22].
Life-style risk factors are the most important potential
explanation for these regional differences. According to
the Global health risks report on mortality and burden
of disease attributable to major risk factors, physical
inactivity, risky alcohol consumption, smoking, low fruit
and vegetable consumption, as well as obesity, hyperten-
sion and diabetes cause cardiovascular disease in more
than half of all cases [25]. North-South differences in
these risk factors within Germany has been demon-
strated in a number of previous studies [18, 26–31]. The
GEDA study reported a prevalence of physical inactivity
of 41.4% in men and 41.2% in women in the Northeast
and 33.3% in men and 33.1% in women in the South.
Furthermore, the prevalence of smoking was 35.1% in
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men and 23.2% in women in the Northeast compared to
30.6% in men and 23.0% in women in the South. In
addition, the prevalence of obesity was 20.0% in men
and 21.3% in women in the Northeast and 16.4% in men
and 14.7% in women in the South. Finally, the
prevalence of hypertension was 38.9% in both sexes in
the Northeast and 32.0% in men and 28.0% in women in
the South [26]. The data from the population-based
Table 2 Components of metabolic syndrome by cohort, categorised by normal glucose tolerance, prediabetes, newly diagnosed
diabetes and known diabetes
Normal glucose tolerance Prediabetes Newly diagnosed diabetes Known diabetes
Total % (n)
KORA-F4 60.5 (1774) 28.4 (834) 3.0 (87) 8.1 (237)
SHIP-TREND 45.3 (1151) 34.9 (885) 5.6 (142) 14.2 (361)
Age (years) mean (std)
KORA-F4 51.5 (12.2) 60.6 (11.3) 64.8 (9.7) 66.9 (8.6)
SHIP-TREND 48.6 (12.3) 55.2 (11.7) 61.6 (9.3) 65.0 (9.3)
Body mass index (kg/m2) mean (SD)
KORA-F4 26.3 (4.3) 29.1 (4.7) 31.1 (4.4) 31.5 (5.4)
SHIP-TREND 26.3 (4.3) 29.3 (4.7) 31.3 (5.2) 33.0 (5.8)
Systolic blood pressure (mmHg) mean (SD)
KORA-F4 117.4 (16.9) 128.1 (18.5) 132.6 (16.8) 132.7 (19.6)
SHIP-TREND 121.0 (15.7) 130.7 (16.8) 135.7 (19.3) 138.5 (19.9)
Diastolic blood pressure (mmHg) mean (SD)
KORA-F4 74.2 (9.6) 77.3 (10.2) 77.9 (10.5) 74.6 (10.5)
SHIP-TREND 75.3 (9.4) 79.3 (9.7) 79.1 (10.8) 78.4 (10.8)
Fasting glucose (mmol/l)
KORA-F4 5.0 (0.3) 5.7 (0.5) 6.7 (1.3) NA
SHIP-TREND 5.1 (0.3) 5.9 (0.4) 7.3 (1.8) NA
2-h glucose (mmol/l)
KORA-F4 5.3 (1.1) 7.3 (1.8) 12.0 (2.8) NA
SHIP-TREND 5.5 (1.1) 7.1 (1.7) 12.6 (3.5) NA
HbA1c (%) mean (SD)
KORA-F4 5.3 (0.3) 5.6 (0.3) 6.1 (0.7) 6.8 (1.1)
SHIP-TREND 5.1 (0.5) 5.3 (0.5) 5.9 (1.0) 6.7 (1.3)
HbA1c (mmol/mol) mean (SD)
KORA-F4 34.7 (3.2) 37.6 (3.7) 43.2 (7.6) 51.1 (12.5)
SHIP-TREND 32.3 (5.9) 34.7 (5.6) 41.1 (10.8) 49.8 (13.7)
HOMA-IR median (IQR)
KORA-F4 1.7 (1.2–2.3) 2.8 (2.0–4.2) 5.3 (3.2–7.3) 5.2 (3.5–8.1)
SHIP-TREND 1.9 (1.3–2.6) 3.2 (2.3–4.6) 5.9 (3.7–8.4) NA
HDL-cholesterol (mmol/l) mean (SD)
KORA-F4 1.5 (0.4) 1.4 (0.4) 1.3 (0.3) 1.2 (0.3)
SHIP-TREND 1.5 (0.4) 1.4 (0.3) 1.3 (0.4) 1.2 (0.3)
Triglycerides (mmol/l) median (IQR)
KORA-F4 1.0 (0.7–1.5) 1.4 (1.0–2.0) 1.8 (1.2–2.6) 1.6 (1.1–2.3)
SHIP-TREND 1.1 (0.8–1.5) 1.4 (1.1–2.0) 1.9 (1.3–2.8) 2.1 (1.5–3.0)
hsCRP (mg/l)a median (IQR)
KORA-F4 0.9 (0.5–1.9) 1.4 (0.7–2.7) 2.8 (1.2–4.7) 1.8 (0.9–3.2)
SHIP-TREND 1.0 (0.6–2.1) 1.3 (0.7–2.5) 1.9 (0.9–3.7) 2.1 (1.0–4.2)
Macrovascular disease % (n)
KORA-F4 5.3 (94) 11.1 (92) 12.6 (11) 24.9 (59)
SHIP-TREND 6.1 (70) 10.0 (88) 19.7 (28) 32.8 (118)
Results are means (± SD), percentages or medians (IQR)
NA not assessed
aHigh-sensitivity C - reactive protein. Participants with hsCRP > 10mg/l were excluded, SHIP-TREND: N = 175, KORA-F4: N = 112
Significant p-values for study differences using the step-down Bonferroni correction (the level of significance p < 0.05) are highlighted in bold
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German Health Interview and Examination Survey
conducted in the years 2008–2011 with 7074 partici-
pants reported a prevalence of hypertension of 36.6% in
men and 30.5% in women in the Northeast and 31.3% in
men and 25.9% in women in the South [30]. Another
study published in 2006 on regional differences in smok-
ing among adults in Germany found a prevalence of
current smokers of 37.8% in men and 28.5% in women
in SHIP (Northeast) and 34.0% in men and 22.4% in
women in KORA-S4 (South) [27]. A further national
cross-sectional study with 35,869 participants,
performed in 2005, showed a higher prevalence of
overweight of 39.2% in the Northeast and 36.3% in the
South [28]. A further analysis to regional differences in
the prevalence of the metabolic syndrome in Germany,
based on the same data, showed that the metabolic
syndrome was more frequent in the Northeast (26.2%)
than in the South of Germany (21.4%) [29]. According
to GEDA study, the prevalence of risky alcohol
consumption in men was slightly higher in the North
than in the South of Germany (34.8% vs. 32.9%) [26]. In
our study we were not able to analyse alcohol
Table 3 Multivariate logistic regression analysis for association between macrovascular disease, geographical region and risk factors
in people with known diabetes and in the general population
Variable Macrovascular disease (yes vs. no)
Known diabetes
Macrovascular disease (yes vs. no)
General population
OR (95% Cl) p-value OR (95% Cl) p-value
Model A
SHIP-TREND (vs. KORA-F4) 1.66 (1.14–2.43) 0.009 1.76 (1.46–2.12) < 0.001
Men (vs. women) 1.73 (1.18–2.52) 0.005 2.20 (1.81–2.67) < 0.001
Age (per year, continuous) 1.05 (1.03–1.07) < 0.001 1.09 (1.08–1.10) < 0.001
Model B
SHIP-TREND (vs. KORA-F4) 1.70 (1.11–2.62) 0.015 1.78 (1.44–2.19) < 0.001
Men (vs. women) 1.50 (0.93–2.41) 0.098 1.97 (1.57–2.47) < 0.001
Age (per year, continuous) 1.05 (1.02–1.08) 0.001 1.07 (1.05–1.08) < 0.001
BMI≥ 25 kg/m2 (vs. < 25 kg/m2) 2.55 (0.85–7.65) 0.096 1.39 (1.01–1.93) 0.046
BMI≥ 30 kg/m2 (vs. < 25 kg/m2) 1.91 (0.65–5.64) 0.241 1.14 (0.80–1.61) 0.466
hsCRP (mg/l)a (continuous) 1.15 (0.90–1.47) 0.254 1.04 (0.92–1.17) 0.534
Hypertension (vs. no) 2.35 (0.94–5.88) 0.069 3.47 (2.57–4.68) < 0.001
Hyperlipidemia (vs. no) 3.86 (2.41–6.18) < 0.001 3.34 (2.70–4.14) < 0.001
Smoker (vs. never smoker) 1.47 (0.73–2.97) 0.278 1.16 (0.81–1.64) 0.417
Ex-smoker (vs. never-smoker) 1.58 (0.98–2.55) 0.061 1.45 (1.15–1.84) 0.002
Low/middle education (vs. high education) 0.92 (0.51–1.64) 0.767 1.22 (0.94–1.59) 0.134
< 1 h physical activity (vs. > 1 h) 0.96 (0.62–1.47) 0.837 1.01 (0.82–1.24) 0.945
Model C
SHIP-TREND (vs. KORA-F4) 1.66 (1.11–2.49) 0.014 1.63 (1.33–2.00) < 0.001
Men (vs. women) 1.49 (0.97–2.29) 0.070 1.89 (1.52–2.34) < 0.001
Age (per year, continuous) 1.05 (1.02–1.08) 0.001 1.06 (1.05–1.08) < 0.001
BMI≥ 25 kg/m2 (vs. < 25 kg/m2) 1.85 (0.67–5.10) 0.237 1.39 (1.01–1.92) 0.041
BMI≥ 30 kg/m2 (vs. < 25 kg/m2) 1.72 (0.64–4.66) 0.287 1.15 (0.82–1.61) 0.419
Hypertension (vs. no) 2.79 (1.13–6.87) 0.026 3.48 (2.59–4.68) < 0.001
Hyperlipidemia (vs. no) 3.48 (2.25–5.36) < 0.001 3.16 (2.57–3.88) < 0.001
Smoker (vs. never smoker) 1.27 (0.66–2.45) 0.477 1.10 (0.79–1.54) 0.572
Ex-smoker (vs. never-smoker) 1.51 (0.97–2.34) 0.066 1.48 (1.18–1.86) 0.001
Known diabetes (vs. normal glucose tolerance) – – 1.37 (1.03–1.84) 0.033
Prediabetes (vs. normal glucose tolerance) – – 0.86 (0.67–1.10) 0.226
Newly diagnosed diabetes (vs. normal glucose tolerance) – – 0.99 (0.64–1.52) 0.950
BMI body mass index, OR odds ratio, CI confidence interval
aHigh-sensitivity C - reactive protein. Participants with hsCRP > 10mg/l were excluded, SHIP-TREND: N = 175, KORA-F4: N = 112
Significant regional differences (p < 0.05) are highlighted in bold
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consumption because of different assessment methods
in SHIP-TREND and KORA-F4.
Another aspect that needs to be discussed is that the
Northeastern region of SHIP-TREND and the Southern
region of KORA-F4 were located in two different states
from 1949 to 1990 (GDR and FRG). These states differed
considerably in their legislation, economic system, health
care [32] as well as cardiovascular risk factors. As an
example, people in the GDR had a higher frequency of
overweight and obesity, physical inactivity, smoking and
consumption of alcohol and soft drinks [24, 33, 34]. The
most likely explanation for the higher frequency of over-
weight and obesity is that the availability of certain foods
on the market had been limited in the GDR. As a result,
the consumption of vegetable oil, fresh fruits and vegeta-
bles was lower and the intake of fatty foods, like
sausages much higher [35]. More than 25 years after re-
unification there are still diversities in risk determinants,
which might be of importance for the different preva-
lence of risk factors for macrovascular disease [24].
Table 4 Multivariate logistic regression analysis for association between myocardial infarction or stroke, geographical region and risk
factors
Variable Myocardial infarction or stroke (yes vs. no)
Known diabetesa
Myocardial infarction or stroke (yes vs. no)
General populationb
OR (95% Cl) p-value OR (95% Cl) p-value
Model A
SHIP-TREND (vs. KORA-F4) 1.14 (0.69–1.89) 0.600 1.34 (1.01–1.78) 0.004
Men (vs. women) 2.05 (1.20–3.51) 0.009 2.58 (1.90–3.51) < 0.001
Age (per year, continuous) 1.07 (1.04–1.11) < 0.001 1.10 (1.09–1.12) < 0.001
Model B
SHIP-TREND (vs. KORA-F4) 1.09 (0.62–1.94) 0.764 1.31 (0.95–1.79) 0.098
Men (vs. women) 1.92 (0.96–3.84) 0.065 2.30 (1.60–3.31) < 0.001
Age (per year, continuous) 1.10 (1.05–1.14) < 0.001 1.08 (1.06–1.10) < 0.001
BMI≥ 25 kg/m2 (vs. < 25 kg/m2) 1.53 (0.38–6.23) 0.555 1.08 (0.66–1.80) 0.753
BMI≥ 30 kg/m2 (vs. < 25 kg/m2) 1.60 (0.40–6.36) 0.506 0.93 (0.55–1.58) 0.782
hsCRP (mg/l)c (continuous) 1.30 (0.93–1.81) 0.121 1.09 (0.91–1.31) 0.344
Hypertension (vs. no) 1.29 (0.35–4.67) 0.703 3.58 (2.08–6.19) < 0.001
Hyperlipidemia (vs. no) 4.27 (2.08–8.77) < 0.001 4.76 (3.31–6.85) < 0.001
Smoker (vs. never smoker) 2.93 (1.18–7.27) 0.021 1.96 (1.17–3.29) 0.012
Ex-smoker (vs. never-smoker) 1.48 (0.77–2.86) 0.243 1.69 (1.18–2.42) 0.004
Low/middle education (vs. high education) 1.17 (0.52–2.64) 0.699 1.68 (1.08–2.61) 0.022
< 1 h physical activity (vs. > 1 h) 0.80 (0.45–1.43) 0.451 1.16 (0.85–1.60) 0.355
Model C
SHIP-TREND (vs. KORA-F4) 1.11 (0.66–1.87) 0.689 1.21 (0.89–1.64) 0.229
Men (vs. women) 1.74 (0.96–3.16) 0.071 2.23 (1.58–3.14) < 0.001
Age (per year, continuous) 1.08 (1.04–1.12) < 0.001 1.08 (1.06–1.09) < 0.001
Hypertension (vs. no) 2.07 (0.61–7.08) 0.245 3.32 (1.99–5.56) < 0.001
Hyperlipidemia (vs. no) 4.28 (2.21–8.26) < 0.001 4.74 (3.35–6.72) < 0.001
Smoker (vs. never smoker) 1.89 (0.82–4.35) 0.136 1.72 (1.05–2.81) 0.031
Ex-smoker (vs. never-smoker) 1.35 (0.76–2.42) 0.311 1.62 (1.16–2.27) 0.005
Low/middle education (vs. high education) 1.43 (0.66–3.13) 0.369 1.70 (1.12–2.58) 0.013
Known diabetes (vs. normal glucose tolerance) – – 1.37 (0.91–2.06) 0.130
Prediabetes (vs. normal glucose tolerance) – – 0.93 (0.63–1.36) 0.696
Newly diagnosed diabetes (vs. normal glucose tolerance) – – 0.94 (0.49–1.81) 0.862
BMI body mass index, OR odds ratio, CI confidence interval
aSHIP-TREND: N = 47, KORA-F4: N = 31
bSHIP-TREND: N = 105, KORA-F4: N = 109
cHigh-sensitivity C - reactive protein. Participants with hsCRP > 10mg/l were excluded, SHIP-TREND: N = 175, KORA-F4: N = 112
Significant regional differences (p < 0.05) are highlighted in bold
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Furthermore, the access to healthcare [36] and factors
of the physical and built environment [37] may con-
tribute to the differences in mortality and morbidity
within Germany. Moreover, the individual socioeco-
nomic status (income, education, occupation) may
also play a role, in so far as the occurrence of cardio-
vascular disease is the highest among individuals in
poorer socio-economic circumstances [38]. Further
studies showed, that not only individuals with low
socio-economic status, but also persons who live in
socioeconomically deprived areas are at increased risk
of obesity and type 2 diabetes [17, 39]. Finally, mental
health could play a crucial role. Various epidemiologic
and basic science studies established a connection
between cardiovascular disease and depression,
psychological stress and anxiety [40]. In the national
surveillance by the Robert Koch-Institute (2014)
differences in the prevalence of mental disorders
between former GDR (Northeast) and former FGR
(South) were also reported (36.6% in women and
20.4% in men in former GDR, 33.7% in women and
23.0% in men in former FRG) [24]. Furthermore, rou-
tine data from 2000 to 2013 of the Techniker
Krankenkasse, one of the biggest statutory health
funds in Germany covering about 9% of the popula-
tion, showed that the number of sick days due to
depression was higher in the region of SHIP-TREND
than in region of KORA-F4 (109 vs. 90 per 100
employed persons, respectively) [41].
While many studies worldwide reported geographic
differences within countries in macrovascular disease or
in cardiovascular mortality in the general population
[42–49], only few studies reported the regional
variations among people with type 2 diabetes. The data
from the French national mortality registry from 2002
showed that the burden of diabetes-related mortality
was higher in the Northeast than in the West of France
[50]. To our knowledge, our research is the first inter-
national study, analysing these regional differences in
people with type 2 diabetes.
Finally, it is noteworthy that the all-cause mortality as
well as the incidence rates for cardiovascular disease
among people with type 2 diabetes have fallen consider-
ably in recent years worldwide [51, 52]. Observations
from the USA, based on the national surveillance data,
showed that the rates of myocardial infarction and
stroke in people with type 2 diabetes declined between
1990 and 2010 by 68 and 53%, respectively [53]. Further-
more, a retrospective cohort study from Canada, based
on 670,602 people with and 9,190,721 people without
diabetes, reported that the rates of patients having acute
myocardial infarction or stoke decreased between 1992
and 2000 more in people with diabetes than in people
without diabetes [54]. A study from Germany, including
14,578 individuals with myocardial infarction, also
showed a significant decrease in the incidence of
myocardial infarction in women with diabetes between
1985 and 2006 [55]. These findings suggest that care and
management of patients with diabetes has been
improved in recent decades, which leads to better
primary and secondary prevention of diabetes-related
complications [52, 54]. Thus, it was important that the
time of data assembling of both surveys (SHIP-TREND,
KORA-F4) was comparable.
Interestingly, our analysis revealed that ex-smokers
had a greater risk for macrovascular disease than active
smokers. A similar observation was reported in a study
from Germany on regional variability of lifestyle factors
and hypertension with prediabetes and newly diagnosed
diabetes [18]. Possible explanations for these observa-
tions could be an increased intake of high-caloric food
after quitting smoking and the resulting risks, such as
overweight [56], or survival bias due to increasing
survival of former smokers in comparison to individuals
who continue to smoke [57]. Another explanation might
be that the ex-smokers had stopped smoking because of
a previous heart attack, stroke or coronary heart disease.
As both studies are of cross-sectional design, unfortu-
nately cause and effect relationships cannot be detected.
The major strength of our study is a large
population-based sample of well-characterised partici-
pants including detailed data on lifestyle and multiple
risk factors, measured following common standardised
protocols in SHIP-TREND and KORA-F4. Several limi-
tations of the study should be mentioned. First, it is pos-
sible that the prevalence of macrovascular disease was
underestimated in the South of Germany since in the
follow-up survey (KORA-F4) persons with higher mor-
bidity most likely had a higher likelihood of not attend-
ing the follow-up investigation. Second, in SHIP-TREND
the diabetes status was obtained by self-reported physi-
cian’s diagnosis only. However, results of several studies
showed that the accuracy of self-reports for diabetes is
generally high [58, 59]. Furthermore, the measurements
of glucose values were based on plasma in SHIP-TREND
and serum in KORA-F4. Nevertheless, the measure-
ments were compared in SHIP-TREND and showed a
high degree of agreement between both methods.
Finally, the SHIP-TREND and KORA-F4 are restricted
to participants of German nationality only, so that the
results cannot be referred to the current resident
population of Germany without further assumptions.
In our analysis we found relatively high prevalence of
self-reported high blood pressure (48.9% in SHIP-TREND,
48.6% in KORA-F4), especially in people with diabetes
(80.0% in SHIP-TREND, 84.8% in KORA-F4). The most
likely explanation is that the blood pressure status was
obtained by the question: “Have you ever had a diagnosis
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of an increased or high blood pressure?”, which could have
led to an overestimation of the prevalence of current high
blood pressure.
Finally, we defined our outcome variable “macrovascu-
lar disease” as having previous myocardial infarction,
stroke or coronary angiography. Coronary angiography
was included in the outcome variable because it is an
important indicator for coronary heart disease [15]. The
most common indication for a coronary angiography in
Germany is angina pectoris (24.3%), followed by acute
myocardial infarction (20.1%) and chronic ischemic
heart disease (19.6%). Further reasons for catheter exam-
ination are sore throat and chest pain (3.1%) and athero-
sclerosis (0.4%) [15]. However, in our sensitivity analysis,
we also did an analysis in which solely myocardial infarc-
tion and stroke were included as outcomes to verify the
results. The analysis showed that the ORs for the differ-
ence between SHIP-TREND und KORA-F4 regions
decreased in all models, but remained significant in the
age- and sex-adjusted model for the general population.
Although the number of coronary angiographies carried
out varies widely within Germany, it is comparable
between the SHIP-TREND und KORA-F4 regions
(SHIP-TREND: 125–152, KORA-F4: 96–124 coronary
angiographies per 10,000 persons per year) [15].
Therefore, the result of the sensitivity analysis is very
likely attributable to the small number of participants
with myocardial infarction or stroke only (SHIP-TREND:
105 and KORA-F4: 109 in the general population,
SHIP-TREND: 47 and KORA-F4: 31 in the participants
with known diabetes).
Conclusions
In conclusion, there is an indication that people in the
Northeast have a higher prevalence of macrovascular
disease than in the South of Germany. In particular, the
difference is more relevant in persons with known type
2 diabetes. Prevention strategies and health-care plan-
ning need to consider these regional differences in mor-
bidity within Germany for better identification of
high-risk groups. Further studies are needed to investi-
gate other risk factors that can explain these regional
differences, such as geographical variations in medical
care services, regional deprivation or the impact of stress
and depression.
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